Genomics of the Psychedelic Frontier: Inside Tryptomics with Chris Pauli

In this episode of Inside the Revival on Healthcare NOW Radio, host Jim Tate sits down with Chris Pauli, Co-Founder and Molecular Biologist at Tryptomics, a Colorado-based biotech laboratory pioneering testing and research services for psychoactive plants and fungi. From his early work sequencing the cannabis genome to building one of the first dedicated psychedelic testing labs, Pauli brings a rigorous scientific lens to a field that urgently needs one. The conversation covers the extraordinary variability in psilocybin potency across mushroom strains and flush cycles; the case for full-spectrum "ensemble" medicine over single-compound isolates; the emerging science of pharmacogenomics and what it could mean for personalized psychedelic therapy; Colorado's landmark Natural Medicine Health Act (Proposition 122) and the regulatory challenges ahead for ibogaine and DMT; and the troubling proliferation of synthetic tryptamines in the unregulated market. Pauli also introduces a critical reframe: replacing the borrowed cannabis concept of the "entourage effect" with what Tryptomics colleague Ian Bollinger calls the ensemble effect, a metaphor that recognizes every alkaloid as an integral part of the orchestra, not merely support for a VIP molecule. Candid, technically grounded, and forward-looking, this episode is essential listening for clinicians, policymakers, researchers, and anyone navigating the rapidly evolving landscape of natural medicine.